ABSTRACT
BACKGROUND: The evolution of radiotherapy over recent decades has reintroduced the hypofractionation for many tumor sites with similar outcomes to those of conventional fractionated radiotherapy. The use of hypofractionation in locally advanced head and neck cancer (LAHNC) has been already used, however, its use has been restricted to only a few countries. The aim of this trial was to evaluate the safety and feasibility of moderate hypofractionated radiotherapy (HYP-RT) with concomitant cisplatin (CDDP). METHODS: This single-arm trial was designed to evaluate the safety and feasibility of HYP-RT with concomitant CDDP in LAHNC. Stage III and IV patients withnonmetastatic disease were enrolled. Patients were submitted to intensity modulatedradiation therapy, which comprised 55 Gy/20 fractions to the gross tumor and44-48 Gy/20 fractions to the areas of subclinical disease. Concomitant CDDPconsisted of 4 weekly cycles of 35 mg/m2. The primary endpoints were the treatment completion rate and acute toxicity. RESULTS: Twenty patients were enrolled from January 2015 to September 2016, and 12 (60%) were classified as unresectable. All patients completed the total dose of radiotherapy, and 19 patients (95%) received at least 3 of 4 cycles of chemotherapy. The median overall treatment time was 29 days (27-34). Grade 4 toxicity was reported twice (1 fatigue and 1 lymphopenia). The rates of grade 3 dermatitis and mucositis were 30% and 40%, respectively, with spontaneous resolution. Nasogastric tubes were offered to 15 patients (75%) during treatment; 4 patients (20%) needed feeding tubes after 2 months, and only 1 patient needed a feeding tube after 12 months. CONCLUSION: HYP-RT with concomitant CDDP was considered feasible for LAHNC, and the rate of acute toxicity was comparable to that of standard concomitant chemoradiation. A feeding tube was necessary for most patients during treatment. Further investigation of this strategy is warranted. TRIAL REGISTRATION: ClinicalTrials, NCT03194061 . Registered 21 Jun 2017 - Retrospectively registered.
Subject(s)
Carcinoma, Squamous Cell , Chemoradiotherapy/adverse effects , Cisplatin , Head and Neck Neoplasms , Aged , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/radiotherapy , Cisplatin/administration & dosage , Cisplatin/adverse effects , Female , Head and Neck Neoplasms/drug therapy , Head and Neck Neoplasms/radiotherapy , Humans , Male , Middle Aged , Radiation Dose HypofractionationABSTRACT
BACKGROUND: The purpose of this phase II trial was to evaluate the tolerability, safety, and efficacy of a non-5-fluorouracil (5-FU)-based induction chemotherapy followed by chemoradiotherapy (CRT) for patients with locally advanced head and neck squamous cell carcinoma (HNSCC). METHODS: Sixty patients with stage III to IV HNSCC were treated with induction paclitaxel and cisplatin (TP; paclitaxel 175 mg/m(2) and cisplatin 80 mg/m(2) , 3 cycles) followed by CRT (cisplatin 100 mg/m(2) ; D1, 22, and 43 of radiotherapy). RESULTS: Fifty-six patients (93.3%) completed 3 cycles of induction TP (no treatment-related deaths), 52 (86.7%) completed definitive CRT per protocol (adverse event [AE] grade ≥2 in 53.3%). The overall response rate after induction TP was 82.5% for patients with resectable disease and 55.5% for unresectable disease (p = .023), and complete response (CR) rate after CRT was 70.0% for patients with resectable disease and 30.0% for unresectable disease (p = .005). CONCLUSION: Induction TP followed by cisplatin based-CRT was well-tolerated, safe, and had high overall response rate in selected patients with locally advanced HNSCC. © 2015 Wiley Periodicals, Inc. Head Neck 38: E970-E980, 2016.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Squamous Cell/therapy , Chemoradiotherapy , Cisplatin/therapeutic use , Head and Neck Neoplasms/therapy , Paclitaxel/therapeutic use , Adult , Aged , Female , Fluorouracil , Humans , Male , Middle Aged , Prospective StudiesABSTRACT
Introdução: A abordagem cervical em pacientes portadores decarcinoma epidermoide (CE) de cavidade oral classificados comoT1 ou T2 N0 ainda é controversa. A pesquisa do linfonodo sentinela(PLS), representa um menor risco de morbidades para o pacientecom uma boa acurácia para detecção de metástases ocultas.Objetivo: Avaliar a evolução de pacientes submetidos à PLS empescoço clinicamente N0. Método: É um estudo retrospectivoque avaliou os pacientes portadores de CE de cavidade oralclassificados como T1 ou T2 N0 submetidos ressecção do tumorprimário e PLS entre Junho de 2008 até Fevereiro de 2011 noHospital de Câncer de Barretos. Resultados: Foram incluídos 26pacientes, a maioria eram homens (73,0%), a média de idade foide 58 anos e o local mais frequente dos CE foi a língua (50,0%).Os carcinomas foram estadiados como T1 em 8 pacientes (33,3%)e T2 em 16 (66,7%). A PLS mostrou-se positiva em 5 pacientes(19,2%). Todos os pacientes em que a pesquisa do LS mostrousepositiva, foram submetidos a esvaziamento cervical seletivo.O seguimento médio dos pacientes foi de 11 meses, nesteperíodo a recorrência no pescoço homolateral a PLS ocorreu em2 pacientes (7,7%). Conclusão: Neste estudo o LS foi positivo19,2% e a recidiva cervical ocorreu em 7,7%. Observou-se que atécnica de PLS é factível e segura como único procedimento paraestadiamento do pescoço apresentando resultados oncológicoscomparáveis à realização do esvaziamento cervical seletivo comoprimeira opção para estes pacientes.
